A Phase 4 interventional study of Gentamicin + narrow spectrum betalactam and Cefotaxime in Sepsis, sponsored by University Hospital, Akershus. Recruiting at 15 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by University Hospital, Akershus · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Sepsis with a site in Norway — 4 open to participants now, 4 under way, none of them phase 3. Sepsis · Norway.
Among the 12 studies in Sepsis with a site in Norway, this one is one of 2 that started in 2026, is one of 3 in phase 4, and was the 11th registered.
2,425 studies on the registry are indexed under Sepsis; 543 are open to participants now.
Browse Sepsis studies →4 of the 12 studies in Sepsis with a site in Norway are open now. Recruiting first, the newest first:
Ole Hyldegaard · Sites in Norway, Belgium
Ages 18+
St. Olavs Hospital · Sites in Norway
Ages 0 min–12 mo · Healthy volunteers
Oslo University Hospital · Sites in Norway
Ages 18+
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 319 Sepsis studies recruiting now, 212 (66%) set no upper age limit and 52 (16%) stop at 75 or younger; 67 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,900 is above the median of 102 across 1,169 interventional studies indexed under Sepsis.
Median enrollment 1,690 across the 4 interventional studies, 250 across the 7 observational. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 10 most frequent:
University Hospital, Akershus is the lead sponsor of 125 studies on the registry; 27 are open to participants now.
University Hospital, Akershus has 1 study filed under Sepsis — fewer than ten, so there is no comparison to draw.
1 of the studies in Sepsis with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04203979Oslo University HospitalSepsis: From Syndrome to Personalized Care | 2027-07-31 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies in Sepsis with a site in Norway, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Norwegian guidelines for empirical antibiotic therapy in suspected community acquired sepsis recommend the combination of narrow spectrum betalactam and aminoglycoside as the first choice, but broad spectrum betalactams are considered equally appropriate, effective, and safe. However, fear of renal complications due to gentamicin and concern for lacking evidence for efficiency commonly leads to the use of broad spectrum betalactam therapy, a larger driver of antibiotic resistance.
In patients with suspected community acquired sepsis, the investigators hypothesize that empirical combination therapy with narrow spectrum betalactams and aminoglycosides is safe and non-inferior to empirical therapy with broad spectrum betalactams. More specifically, the investigators hypothesize that the proportion of patients with acute kidney injury or death will be similar between these two treatment groups. Furthermore, the investigators hypothesize that the aminoglycoside-based regimen has lesser impact on the gut microbiome. Antimicrobial resistance is one of the most urgent health threats of our time, and Norwegian hospitals were required but failed to reduce the use of broad-spectrum antibiotics with 30% by the end of 2020. In this context, novel initiatives aiming at reducing use of antibiotics are direly needed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
Drug: Gentamicin + narrow spectrum betalactam
Empirical therapy for suspected community-acquired sepsis with broad spectrum betalactam (either one of cefotaxime or piperacillin-tazobactam)
Drug: Cefotaxime · Drug: Piperacillin-tazobactam
Empirical therapy for suspected community-acquired sepsis with gentamicin + narrow spectrum betalactam (either one of penicillin, ampicillin, or cloxacillin)
Empirical therapy for suspected community-acquired sepsis with cefotaxime
Empirical therapy for suspected community-acquired sepsis with piperacillin-tazobactam
30-day mortality
All-cause mortality up to 30 days after randomization
Time frame: Up to 30 days after randomization
30-day acute kidney injury
Any acute kidney injury up to 30 days after randomization
Time frame: Up to 30 days after randomization
In-hospital mortality
All-cause mortality during index hospitalization
Time frame: During index hospitalization (commonly up to 30 days)
Duration of hospital stay
Duration of index hospitalization (days)
Time frame: During index hospitalization (commonly up to 30 days)
Duration of intensive care stay
Duration of stay in intensive care unit (days)
Time frame: During index hospitalization (commonly up to 30 days)
Duration of ventilator therapy
Duration of therapy with invasive mechanical ventilation (days)
Time frame: During index hospitalization (commonly up to 30 days)
Duration of vasopressor therapy
Duration of therapy with vasoactive (vasopressor) (days)
Time frame: During index hospitalization (commonly up to 30 days)
Hospital readmissions
Readmission after discharge from index hospitalization
Time frame: Up to 30 days after discharge from index hospitalization
Post-discharge mortality
All-cause mortality after discharge from index hospitalization
Time frame: Up to 30 days after discharge from index hospitalization
Duration of antibiotic treatment
Duration of antibiotic therapy during index hospitalization (days of therapy, DOT)
Time frame: During index hospitalization (commonly up to 30 days)
Plan to share: No — The dataset used in this study is not publicly available, as the Data Protection Authority approval and patient consent do not allow for such publication. The study group welcomes initiatives for cooperation and data access may be granted upon application.
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Jun 2028, 26 months after the start.
Of 65 non-industry phase 4 interventional studies under Sepsis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 26 months is close to that.
Counting every sponsor, half of 66 studies reached it within 25 months; a quarter within 15 and three quarters within 43.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Cefotaxime
University Hospital, Akershus →